Methylprednisolone hemisuccinate and metabolites in urine from patients receiving high-dose corticosteroid therapy.
A reversed-phase high-performance liquid chromatographic (RP-HPLC) method for the measurement of methylprednisolone hemisuccinate (MPHS) and its metabolites methylprednisolone (MP), 20-alpha- (20a-HMP), and 20-beta-hydroxymethylprednisolone (20b-HMP) in urine is described. The metabolites were extracted from urine samples using Extrelut columns and eluted with ethylacetate. The mobile phase for RP-HPLC comprised methanol:citrate buffer:tetrahydrofuran (30:65:5, vol/vol/vol) with UV detection at 251 nm. Fractions were collected, pooled and the metabolites present were identified by gas chromatography-mass spectrometry and normal-phase HPLC (NP-HPLC). By RP-HPLC 30 +/- 7.3% (mean +/- 1 SD) of the dose was detected in the 0-24 h urine sample following a 1 g MPHS infusion to patients with rheumatoid arthritis; MPHS contributed 9.9 +/- 5.0%, MP 12.1 +/- 2.9%, 20a-HMP 7.8 +/- 2.2%, and 20b-HMP 1.0 +/- 0.3%, respectively. A further 1.0 +/- 0.9% of the administered dose was detected in urine collected 24-48 h postinfusion.
Lawson
G J
GJ
Department of Clinical Chemistry, Kent and Sussex Hospital, Tunbridge Wells, England.
Chakraborty
J
J
Dumasia
M C
MC
Baylis
E M
EM
D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000652:urine; D002851:Chromatography, High Pressure Liquid; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D006868:Hydrolysis; D008775:Methylprednisolone / Q000652:urine; D008776:Methylprednisolone Hemisuccinate / Q000627:therapeutic use / Q000652:urine*; D013056:Spectrophotometry, Ultraviolet
D008776:Methylprednisolone Hemisuccinate; D008775:Methylprednisolone